Greykasell Wealth Strategies »

Crispr Therapeutics shares owned by Greykasell Wealth Strategies

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Greykasell Wealth Strategies from 13F filings

Historical chart of Greykasell Wealth Strategies investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Greykasell Wealth Strategies consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Greykasell Wealth Strategies

Quarter filed Position value Share count Share price at filing
2026-06-30 $3.7k 68 54.54
2026-03-31 $3.2k 68 47.57
2025-12-31 $3.6k 68 52.44
2025-09-30 $4.4k 68 64.81
2025-06-30 $3.3k 68 48.65
2025-03-31 $2.3k 68 34.03

More positions owned by Greykasell Wealth Strategies

Ishares Global 100 Etf Etf (IOO)
Apple Stock (AAPL)
Alphabet Inc Cap Stk Cl A Stock (GOOGL)
Spdr Gold Shares Etf (GLD)
Ishares Core S&p 500 Etf Etf (IVV)
Fidelity Total Bond Etf Etf (FBND)
Ishares Core U.s. Aggregate Bond Etf Etf (AGG)
Ishares Msci Emerging Markets Ex China Etf Etf (EMXC)
Invesco Qqq Trust Series I Etf (QQQ)
Amazon Stock (AMZN)
Ishares Core Msci Eafe Etf Etf (IEFA)
Nvidia Corporation Stock (NVDA)
Kla Corp Stock (KLAC)
Vanguard Ftse Developed Markets Etf Etf (VEA)
Ishares Core S&p Small Cap Etf Etf (IJR)

View all positions for Greykasell Wealth Strategies

Top funds holding Crispr Therapeutics

ARK Investment Management
BlackRock
Orbis Allan Gray
Capital World Investors
State Street Corporation
GSK
Geode Capital Management
Sr One Capital Management
Two Sigma Investments
FMR
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
EcoR1 Capital
UBS Group
Capital Research and Management Company - Division 3

View all funds holding Crispr Therapeutics